Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
31
DSKYF Quote, Financials, Valuation and Earnings
Last price:
$19.27
Seasonality move
:
4.5%
Day range:
$18.97 - $19.51
52-week range:
$17.41 - $29.15
Dividend yield:
2.44%
P/E ratio:
17.38x
P/S ratio:
2.58x
P/B ratio:
3.22x
Volume:
1K
Avg. volume:
74.3K
1-year change:
-19.71%
Market cap:
$35.1B
Revenue:
$12.4B
EPS (TTM):
$1.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DSKYF
Daiichi Sankyo Co., Ltd.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DSKYF
Daiichi Sankyo Co., Ltd.
|
$18.97 | -- | $35.1B | 17.38x | $0.26 | 2.44% | 2.58x |
|
HLOSF
Healios KK
|
$2.10 | -- | $243M | -- | $0.00 | 0% | 308.70x |
|
PPTDF
PeptiDream Inc.
|
$8.85 | -- | $1.1B | 13.79x | $0.00 | 0% | 9.26x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.44 | -- | $492.3M | -- | $0.00 | 0% | 2.47x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DSKYF
Daiichi Sankyo Co., Ltd.
|
14.95% | 0.367 | 4.82% | 1.59x |
|
HLOSF
Healios KK
|
34.82% | -0.193 | 7.46% | 1.83x |
|
PPTDF
PeptiDream Inc.
|
24.85% | 0.074 | 6.74% | 1.48x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
48.47% | 1.070 | 73.82% | 1.61x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DSKYF
Daiichi Sankyo Co., Ltd.
|
$2.9B | $580.8M | 16.78% | 18.75% | 16.03% | $311.1M |
|
HLOSF
Healios KK
|
-$798.3K | -$6.6M | -44.36% | -88.96% | -4043.07% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$17.4M | -$6M | -5.23% | -7.06% | -16.33% | -$2.4M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$37.1M | -$8.9M | -9.66% | -19.06% | -17.59% | -$1M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
Daiichi Sankyo Co., Ltd. vs. Competitors
-
Which has Higher Returns DSKYF or HLOSF?
Healios KK has a net margin of 15.52% compared to Daiichi Sankyo Co., Ltd.'s net margin of -9751.87%. Daiichi Sankyo Co., Ltd.'s return on equity of 18.75% beat Healios KK's return on equity of -88.96%.
Company Gross Margin Earnings Per Share Invested Capital DSKYFDaiichi Sankyo Co., Ltd.78.81% $0.30 $12.8B HLOSFHealios KK-491.87% $0.12 $47.9M -
What do Analysts Say About DSKYF or HLOSF?
Daiichi Sankyo Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo Co., Ltd. has higher upside potential than Healios KK, analysts believe Daiichi Sankyo Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings DSKYFDaiichi Sankyo Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is DSKYF or HLOSF More Risky?
Daiichi Sankyo Co., Ltd. has a beta of 0.145, which suggesting that the stock is 85.548% less volatile than S&P 500. In comparison Healios KK has a beta of 0.262, suggesting its less volatile than the S&P 500 by 73.819%.
-
Which is a Better Dividend Stock DSKYF or HLOSF?
Daiichi Sankyo Co., Ltd. has a quarterly dividend of $0.26 per share corresponding to a yield of 2.44%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo Co., Ltd. pays 38.47% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Daiichi Sankyo Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DSKYF or HLOSF?
Daiichi Sankyo Co., Ltd. quarterly revenues are $3.6B, which are larger than Healios KK quarterly revenues of $162.3K. Daiichi Sankyo Co., Ltd.'s net income of $562.3M is higher than Healios KK's net income of $12.4M. Notably, Daiichi Sankyo Co., Ltd.'s price-to-earnings ratio is 17.38x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo Co., Ltd. is 2.58x versus 308.70x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSKYFDaiichi Sankyo Co., Ltd.2.58x 17.38x $3.6B $562.3M HLOSFHealios KK308.70x -- $162.3K $12.4M
-
Which has Higher Returns DSKYF or PPTDF?
PeptiDream Inc. has a net margin of 15.52% compared to Daiichi Sankyo Co., Ltd.'s net margin of -9.39%. Daiichi Sankyo Co., Ltd.'s return on equity of 18.75% beat PeptiDream Inc.'s return on equity of -7.06%.
Company Gross Margin Earnings Per Share Invested Capital DSKYFDaiichi Sankyo Co., Ltd.78.81% $0.30 $12.8B PPTDFPeptiDream Inc.47.44% -$0.03 $437.5M -
What do Analysts Say About DSKYF or PPTDF?
Daiichi Sankyo Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Daiichi Sankyo Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings DSKYFDaiichi Sankyo Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is DSKYF or PPTDF More Risky?
Daiichi Sankyo Co., Ltd. has a beta of 0.145, which suggesting that the stock is 85.548% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.573, suggesting its less volatile than the S&P 500 by 42.666%.
-
Which is a Better Dividend Stock DSKYF or PPTDF?
Daiichi Sankyo Co., Ltd. has a quarterly dividend of $0.26 per share corresponding to a yield of 2.44%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo Co., Ltd. pays 38.47% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Daiichi Sankyo Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DSKYF or PPTDF?
Daiichi Sankyo Co., Ltd. quarterly revenues are $3.6B, which are larger than PeptiDream Inc. quarterly revenues of $36.8M. Daiichi Sankyo Co., Ltd.'s net income of $562.3M is higher than PeptiDream Inc.'s net income of -$3.5M. Notably, Daiichi Sankyo Co., Ltd.'s price-to-earnings ratio is 17.38x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo Co., Ltd. is 2.58x versus 9.26x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSKYFDaiichi Sankyo Co., Ltd.2.58x 17.38x $3.6B $562.3M PPTDFPeptiDream Inc.9.26x 13.79x $36.8M -$3.5M
-
Which has Higher Returns DSKYF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 15.52% compared to Daiichi Sankyo Co., Ltd.'s net margin of -99.41%. Daiichi Sankyo Co., Ltd.'s return on equity of 18.75% beat Nxera Pharma Co., Ltd.'s return on equity of -19.06%.
Company Gross Margin Earnings Per Share Invested Capital DSKYFDaiichi Sankyo Co., Ltd.78.81% $0.30 $12.8B SOLTFNxera Pharma Co., Ltd.73.58% -$0.55 $755.2M -
What do Analysts Say About DSKYF or SOLTF?
Daiichi Sankyo Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Daiichi Sankyo Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings DSKYFDaiichi Sankyo Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is DSKYF or SOLTF More Risky?
Daiichi Sankyo Co., Ltd. has a beta of 0.145, which suggesting that the stock is 85.548% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.018, suggesting its less volatile than the S&P 500 by 98.16%.
-
Which is a Better Dividend Stock DSKYF or SOLTF?
Daiichi Sankyo Co., Ltd. has a quarterly dividend of $0.26 per share corresponding to a yield of 2.44%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo Co., Ltd. pays 38.47% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Daiichi Sankyo Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DSKYF or SOLTF?
Daiichi Sankyo Co., Ltd. quarterly revenues are $3.6B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $50.4M. Daiichi Sankyo Co., Ltd.'s net income of $562.3M is higher than Nxera Pharma Co., Ltd.'s net income of -$50.1M. Notably, Daiichi Sankyo Co., Ltd.'s price-to-earnings ratio is 17.38x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo Co., Ltd. is 2.58x versus 2.47x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSKYFDaiichi Sankyo Co., Ltd.2.58x 17.38x $3.6B $562.3M SOLTFNxera Pharma Co., Ltd.2.47x -- $50.4M -$50.1M
-
Which has Higher Returns DSKYF or STMM?
Stemcell Holdings, Inc. has a net margin of 15.52% compared to Daiichi Sankyo Co., Ltd.'s net margin of --. Daiichi Sankyo Co., Ltd.'s return on equity of 18.75% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DSKYFDaiichi Sankyo Co., Ltd.78.81% $0.30 $12.8B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About DSKYF or STMM?
Daiichi Sankyo Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Daiichi Sankyo Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DSKYFDaiichi Sankyo Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is DSKYF or STMM More Risky?
Daiichi Sankyo Co., Ltd. has a beta of 0.145, which suggesting that the stock is 85.548% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock DSKYF or STMM?
Daiichi Sankyo Co., Ltd. has a quarterly dividend of $0.26 per share corresponding to a yield of 2.44%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo Co., Ltd. pays 38.47% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Daiichi Sankyo Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DSKYF or STMM?
Daiichi Sankyo Co., Ltd. quarterly revenues are $3.6B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Daiichi Sankyo Co., Ltd.'s net income of $562.3M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Daiichi Sankyo Co., Ltd.'s price-to-earnings ratio is 17.38x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo Co., Ltd. is 2.58x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DSKYFDaiichi Sankyo Co., Ltd.2.58x 17.38x $3.6B $562.3M STMMStemcell Holdings, Inc.0.17x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 14.29% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 7.51% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 5.73% over the past day.
